EyePoint Pharmaceuticals Inc
NASDAQ:EYPT

Watchlist Manager
EyePoint Pharmaceuticals Inc Logo
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Watchlist
Price: 18.2 USD -0.49%
Market Cap: 1.5B USD

Wall Street
Price Targets

EYPT Price Targets Summary
EyePoint Pharmaceuticals Inc

Wall Street analysts forecast EYPT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EYPT is 36.8 USD with a low forecast of 20.2 USD and a high forecast of 71.4 USD.

Lowest
Price Target
20.2 USD
11% Upside
Average
Price Target
36.8 USD
102% Upside
Highest
Price Target
71.4 USD
292% Upside
EyePoint Pharmaceuticals Inc Competitors:
Price Targets
OMER
Omeros Corp
107% Upside
053030
Binex Co Ltd
87% Upside
CRMD
CorMedix Inc
50% Upside
ZTS
Zoetis Inc
28% Upside
4552
JCR Pharmaceuticals Co Ltd
6% Downside
195940
HK Inno.N Corp
32% Upside
AETHER
Aether Industries Ltd
27% Upside

Revenue
Forecast

Revenue Estimate
EyePoint Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for EyePoint Pharmaceuticals Inc's revenue is 21%. The projected CAGR for the next 4 years is 58%.

21%
Past Growth
58%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
EyePoint Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
EyePoint Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-65%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EYPT's stock price target?
Price Target
36.8 USD

According to Wall Street analysts, the average 1-year price target for EYPT is 36.8 USD with a low forecast of 20.2 USD and a high forecast of 71.4 USD.

What is EyePoint Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
58%

For the last 13 years the compound annual growth rate for EyePoint Pharmaceuticals Inc's revenue is 21%. The projected CAGR for the next 4 years is 58%.

Back to Top